These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

185 related articles for article (PubMed ID: 32356704)

  • 1. [Therapeutic vaccination for glioblastoma].
    Dietrich PY; Dutoit V
    Med Sci (Paris); 2020 Apr; 36(4):319-322. PubMed ID: 32356704
    [No Abstract]   [Full Text] [Related]  

  • 2. Should dendritic cell-based tumor vaccination be incorporated into standard therapy for newly diagnosed glioblastoma patients?
    Van Gool S; De Vleeschouwer S
    Expert Rev Neurother; 2012 Oct; 12(10):1173-6. PubMed ID: 23082731
    [No Abstract]   [Full Text] [Related]  

  • 3. Vaccine for aggressive brain tumors may prolong survival.
    Health News; 2004 Dec; 10(12):7. PubMed ID: 15645564
    [No Abstract]   [Full Text] [Related]  

  • 4. Immunotherapy for Glioblastoma: Current Progress and Challenges.
    Yu MW; Quail DF
    Front Immunol; 2021; 12():676301. PubMed ID: 34054867
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A pilot study of autologous cancer cell vaccination and cellular immunotherapy using anti-CD3 stimulated lymphocytes in patients with recurrent grade III/IV astrocytoma.
    Wood GW; Holladay FP; Turner T; Wang YY; Chiga M
    J Neurooncol; 2000 Jun; 48(2):113-20. PubMed ID: 11083074
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Dendritic cell immunotherapy for glioblastoma.
    Polyzoidis S; Ashkan K
    Expert Rev Anticancer Ther; 2014 Jul; 14(7):761-3. PubMed ID: 24850137
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Current Immunotherapies for Glioblastoma Multiforme.
    Huang B; Li X; Li Y; Zhang J; Zong Z; Zhang H
    Front Immunol; 2020; 11():603911. PubMed ID: 33767690
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Enhancing dendritic cell-based vaccination for highly aggressive glioblastoma.
    Batich KA; Swartz AM; Sampson JH
    Expert Opin Biol Ther; 2015 Jan; 15(1):79-94. PubMed ID: 25327832
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Dendritic Cell Vaccination of Glioblastoma: Road to Success or Dead End.
    Datsi A; Sorg RV
    Front Immunol; 2021; 12():770390. PubMed ID: 34795675
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Advances in Immunotherapy for Glioblastoma Multiforme.
    Huang B; Zhang H; Gu L; Ye B; Jian Z; Stary C; Xiong X
    J Immunol Res; 2017; 2017():3597613. PubMed ID: 28299344
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Challenging Hurdles of Current Targeting in Glioblastoma: A Focus on Immunotherapeutic Strategies.
    Genoud V; Migliorini D
    Int J Mol Sci; 2021 Mar; 22(7):. PubMed ID: 33800593
    [TBL] [Abstract][Full Text] [Related]  

  • 12. DCVax®-L--developed by Northwest Biotherapeutics.
    Polyzoidis S; Ashkan K
    Hum Vaccin Immunother; 2014; 10(11):3139-45. PubMed ID: 25483653
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Vaccine strategies for glioblastoma: progress and future directions.
    Jackson C; Ruzevick J; Brem H; Lim M
    Immunotherapy; 2013 Feb; 5(2):155-67. PubMed ID: 23413907
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Not Available].
    Baldini C; Romano PM; Varga A; Champiat S; Dumont S; Dhermain F; Louvel G; Marabelle A; Postel-Vinay S; Angevin E; Gazzah A; Ribrag V; Bahleda R; Michot JM; Hollebecque A; Soria JC; Massard C
    Bull Cancer; 2018 Dec; 105 Suppl 1():S59-S67. PubMed ID: 30595200
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Immunotherapy in brain tumors].
    De Carli E; Delion M; Rousseau A
    Ann Pathol; 2017 Feb; 37(1):117-126. PubMed ID: 28111040
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Targeting EGFRvIII for glioblastoma multiforme.
    Yang J; Yan J; Liu B
    Cancer Lett; 2017 Sep; 403():224-230. PubMed ID: 28649003
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Vaccine-based immunotherapy for glioblastoma.
    Thomas AA; Fisher JL; Ernstoff MS; Fadul CE
    CNS Oncol; 2013 Jul; 2(4):331-49. PubMed ID: 25054578
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A randomized controlled phase II trial of vaccination with lysate-loaded, mature dendritic cells integrated into standard radiochemotherapy of newly diagnosed glioblastoma (GlioVax): study protocol for a randomized controlled trial.
    Rapp M; Grauer OM; Kamp M; Sevens N; Zotz N; Sabel M; Sorg RV
    Trials; 2018 May; 19(1):293. PubMed ID: 29801515
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Immunotherapy of surgical malignancies.
    Morse MA; Lyerly HK; Clay TM; Abdel-Wahab O; Chui SY; Garst J; Gollob J; Grossi PM; Kalady M; Mosca PJ; Onaitis M; Sampson JH; Seigler HF; Toloza EM; Tyler D; Vieweg J; Yang Y
    Curr Probl Surg; 2004 Jan; 41(1):15-132. PubMed ID: 14749625
    [No Abstract]   [Full Text] [Related]  

  • 20. [Immunotherapy targeting the Wilms' tumor 1 gene product for patients with malignant brain tumors].
    Hashimoto N; Tsuboi A; Chiba Y; Izumoto S; Oka Y; Yoshimine T; Sugiyama H
    Brain Nerve; 2009 Jul; 61(7):805-14. PubMed ID: 19618858
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.